感染症検査市場 - 世界の産業規模、シェア、動向、機会、予測：製品・サービス別、技術別、疾患別、エンドユーザー別、地域別、競合別、2020年～2030年

感染症検査の世界市場規模は2024年に340億9,000万米ドルに達し、2030年までのCAGRは7.71%で、予測期間中に目覚ましい成長を遂げると予測されています。

細菌、寄生虫、ウイルス、真菌は感染症の原因物質です。これらの疾患の同定と特性解析は、感染症診断学の領域に属します。医師やヘルスケア専門家は、感染症の発見を主に患者の症状や身体検査に頼っています。さまざまな臨床検査を実施して原因病原体を特定し、ヘルスケア提供者が適切な治療を行えるようにします。病原体は、直接接触、水や食品を介した経路、環境中の感染粒子のエアロゾル化、さらには昆虫（蚊など）やマダニを介して感染する可能性があります。

免疫力が低下している人は、特定の感染症に特にかかりやすいです。これには、がん治療中の患者や臓器移植を受けたばかりの患者が含まれます。一般的な感染症に対する予防接種を受けていない人、ヘルスケア従事者、マラリアやデング熱のような蚊が媒介する病原体が存在するリスクの高い地域に旅行する人は、そのリスクが高まります。医師が感染症を診断する際には、さまざまな臨床検査が行われます。世界の感染症検査市場は、様々な伝染病のタイムリーな診断と管理において重要な役割を果たしています。ウイルス感染症や細菌感染症の流行が拡大する中、ヘルスケアシステム全体において、迅速かつ正確で、利用しやすい診断ツールに対するニーズが高まっています。この市場には、HIV、肝炎、結核、インフルエンザ、そして最近ではCOVID-19やサル痘のような新興の脅威といった疾患の検査ソリューションが含まれます。

技術の進歩は主要な促進要因であり、特に分子診断、ポイントオブケア検査、検査室の自動化の採用が顕著です。これらの技術革新は、迅速な納期、感度と特異性の向上、疾病サーベイランスの改善を可能にします。在宅医療や遠隔診療所など分散化したヘルスケア環境の拡大は、携帯可能で使いやすい検査キットの需要をさらに加速させています。例えば、モロッコのバイオテクノロジー企業Moldiagは2024年12月、アフリカ初の国産エムポックス検査キットを発売し、アフリカ大陸のヘルスケア自給率強化における大きなマイルストーンとなりました。この開発により、診断ツールの輸入依存度が低下し、感染症の発生に対応する地域的能力が強化されます。Moldiag社のイニシアチブは、アフリカのバイオテクノロジーインフラストラクチャーを構築し、必要不可欠な診断ソリューションへのタイムリーなアクセスを改善する上で、重要な前進を意味します。

市場促進要因

感染症の流行増加

主な市場課題

不十分な償還

主要市場動向

ポイントオブケア検査（POCT）

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の感染症検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品・サービス別（アッセイ、キット、試薬、機器、サービス、ソフトウェア）
  • 技術別（分子診断、免疫測定、微生物学、その他）
  • 疾患別（肝炎、ヒトパピローマウイルス（HPV）、ヒト免疫不全ウイルス（HIV）、結核（TB）、院内感染症（HAI）、その他）
  • エンドユーザー別（病院、臨床検査室、診断基準検査室、学術調査機関、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の感染症検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の感染症検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の感染症検査市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の感染症検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの感染症検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界の感染症検査市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Biomerieux SA
• Abbott Laboratories Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Quidel Corporation
• Trinity Biotech PLC

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Infectious Disease Testing Market has valued at USD 34.09 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.71% through 2030F. Bacteria, parasites, viruses, and fungi are the causative agents of infectious diseases. The identification and characterization of these diseases fall under the domain of infectious disease diagnostics. Physicians and healthcare professionals primarily rely on patients' symptoms and physical examinations to detect infectious infections. A range of laboratory tests is conducted to determine the causative agents, enabling healthcare providers to administer appropriate medical treatments. Pathogens can be transmitted through direct contact, water or foodborne routes, aerosolization of infected particles in the environment, as well as via insects (such as mosquitoes) and ticks.

Individuals with compromised immune systems are particularly vulnerable to certain infections. This includes those undergoing cancer treatment or recent organ transplant recipients. The individuals who have not been vaccinated against common infectious diseases, healthcare workers, and those traveling to high-risk areas with mosquito-borne pathogens like malaria and dengue fever are at increased risk. Various laboratory tests are employed by doctors to diagnose infectious disorders. The global infectious disease testing market plays a critical role in the timely diagnosis and management of a wide array of contagious illnesses. With the growing prevalence of both viral and bacterial infections, there is a heightened need for rapid, accurate, and accessible diagnostic tools across healthcare systems. The market includes testing solutions for diseases such as HIV, hepatitis, tuberculosis, influenza, and more recently, emerging threats like COVID-19 and monkeypox.

Technological advancements have been a key driver, particularly the adoption of molecular diagnostics, point-of-care testing, and automation in laboratories. These innovations enable quicker turnaround times, increased sensitivity and specificity, and improved disease surveillance. The expansion of decentralized healthcare settings, such as home care and remote clinics, has further spurred demand for portable and easy-to-use test kits. For instance, in December 2024, Moroccan biotech company Moldiag launched Africa's first locally produced mpox test kits, representing a major milestone in strengthening the continent's healthcare self-sufficiency. This development reduces dependence on imported diagnostic tools and enhances regional capacity to respond to infectious disease outbreaks. Moldiag's initiative marks a critical advancement in building Africa's biotechnology infrastructure and improving timely access to essential diagnostic solutions.

Key Market Drivers

Increasing Prevalence of Infectious Diseases

The global infectious disease testing market is experiencing significant growth due to the increasing prevalence of infectious diseases worldwide. The rising prevalence of infectious diseases, particularly tuberculosis (TB), is a key driver of growth in the global infectious disease testing market. According to WHO, TB caused 1.25 million deaths in 2023, making it the world's leading infectious killer, surpassing COVID-19. With an estimated 10.8 million people falling ill globally, including many with drug-resistant TB, the demand for early, accurate, and accessible diagnostic testing continues to rise. The persistent emergence and re-emergence of infectious diseases have heightened the demand for accurate and timely diagnostic solutions. Outbreaks of diseases like COVID-19, Ebola, Zika, and antibiotic-resistant bacterial infections have underscored the need for rapid and efficient testing methods to detect, track, and manage these diseases. The globalization of travel and trade has facilitated the rapid spread of infectious agents across borders, making early detection and containment crucial to prevent outbreaks. This has driven up the demand for robust infectious disease testing infrastructure, including diagnostic assays, testing equipment, and surveillance systems.

The aging global population is more susceptible to infectious diseases, particularly due to compromised immune systems. As a result, there is a heightened focus on early detection and monitoring of infections in elderly individuals, contributing to market growth.

The rising awareness among healthcare professionals and the general public about the importance of early diagnosis and prompt treatment has also fueled demand. Timely infectious disease testing not only aids in better patient care but also helps in preventing the spread of diseases within communities. The increasing prevalence of infectious diseases, coupled with the need for rapid and accurate diagnosis, has led to substantial growth in the global infectious disease testing market. As infectious disease threats continue to evolve, the market is expected to further expand, with ongoing advancements in testing technologies and increased investment in public health infrastructure playing pivotal roles in addressing these global health challenges.

Key Market Challenges

Inadequate Reimbursements

Inadequate reimbursements within healthcare systems can indeed have a negative impact on the demand for global infectious disease testing. Reimbursements play a critical role in healthcare economics, affecting both healthcare providers and patients. When reimbursement rates for infectious disease testing are insufficient, healthcare providers, including hospitals, clinics, and laboratories, may struggle to cover the costs associated with testing. This financial strain can lead to reduced investment in testing infrastructure, limited availability of testing services, and even closures of diagnostic facilities in underserved areas.

Inadequate reimbursement rates can deter healthcare providers from offering a comprehensive range of infectious disease testing services. This may result in reduced access to critical diagnostic tests, leaving patients with limited options for early disease detection and management. Lower reimbursement rates can discourage laboratories and diagnostic companies from investing in research and development to improve testing accuracy, speed, and accessibility. This can stifle innovation and hinder the development of more advanced and cost-effective testing solutions. Reduced access to infectious disease testing due to inadequate reimbursements can exacerbate healthcare disparities, disproportionately affecting underserved populations. These disparities can result in delayed diagnoses and poorer health outcomes in vulnerable communities.

Key Market Trends

Point-of-Care Testing (POCT)

POCT devices that offer rapid results and can be used outside traditional healthcare settings will continue to gain popularity. They are especially valuable in resource-limited and remote areas. POCT devices are designed to be user-friendly and portable, making them accessible even in areas with limited healthcare infrastructure. They can be used in remote clinics, field hospitals, and rural communities, bringing essential diagnostic capabilities closer to patients.

In resource-limited and remote areas, access to centralized laboratories for traditional testing can be challenging. POCT devices offer the advantage of providing immediate results, allowing healthcare providers to diagnose and initiate treatment promptly. This is crucial for managing infectious diseases effectively and preventing their spread. Rapid results from POCT devices mean that patients do not have to wait for days or weeks to receive their test results. This helps alleviate anxiety, enables timely medical decisions, and improves patient satisfaction. POCT devices often require lower initial investments compared to establishing and maintaining a fully equipped laboratory. This cost-effectiveness is particularly valuable for healthcare facilities with limited budgets.

Key Market Players

• Biomerieux SA
• Abbott Laboratories Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Quidel Corporation
• Trinity Biotech PLC

Report Scope:

In this report, the Global Infectious Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infectious Disease Testing Market, By Product & Service:

• Assays
• Kits
• Reagents
• Instruments
• Services & Software

Infectious Disease Testing Market, By Technology:

• Molecular Diagnostics
• Immunoassay
• Microbiology
• Others

Infectious Disease Testing Market, By Disease:

• Hepatitis
• Human Papillomavirus (HPV)
• Human Immunodeficiency Virus (HIV)
• Tuberculosis (TB)
• Hospital-Acquired Infections (HAIs)
• Others

Infectious Disease Testing Market, By End User:

• Hospital and Clinical Laboratories
• Diagnostic Reference Laboratories
• Academic/Research Institutes
• Others

Infectious Disease Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Infectious Disease Testing Market.

Available Customizations:

Global Infectious Disease Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infectious Disease Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Assays, Kits, Reagents, Instruments, Services & Software)
  • 5.2.2. By Technology (Molecular Diagnostics, Immunoassay, Microbiology, Others)
  • 5.2.3. By Disease (Hepatitis, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Hospital-Acquired Infections (HAIs), Others)
  • 5.2.4. By End User (Hospital and Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Infectious Disease Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Technology
  • 6.2.3. By Disease
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Infectious Disease Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Disease
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Infectious Disease Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Disease
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Infectious Disease Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Disease
      • 6.3.3.2.4. By End User

7. Europe Infectious Disease Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Technology
  • 7.2.3. By Disease
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Infectious Disease Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Disease
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Infectious Disease Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Disease
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Infectious Disease Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Disease
      • 7.3.3.2.4. By End User
  • 7.3.4. France Infectious Disease Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Disease
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Infectious Disease Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Disease
      • 7.3.5.2.4. By End User

8. Asia-Pacific Infectious Disease Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Technology
  • 8.2.3. By Disease
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Infectious Disease Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Disease
      • 8.3.1.2.4. By End User
  • 8.3.2. India Infectious Disease Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Disease
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Infectious Disease Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Disease
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Infectious Disease Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Disease
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Infectious Disease Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Disease
      • 8.3.5.2.4. By End User

9. South America Infectious Disease Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Technology
  • 9.2.3. By Disease
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Infectious Disease Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Disease
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Infectious Disease Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Disease
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Infectious Disease Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Disease
      • 9.3.3.2.4. By End User

10. Middle East and Africa Infectious Disease Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Technology
  • 10.2.3. By Disease
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Infectious Disease Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Disease
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Infectious Disease Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Disease
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Infectious Disease Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Disease
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Infectious Disease Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Biomerieux SA
  • 15.1.1. Business Overview
  • 15.1.2. Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc.
• 15.3. Becton, Dickinson and Company
• 15.4. Bio-Rad Laboratories Inc.
• 15.5. Danaher Corporation
• 15.6. F. Hoffmann-La Roche AG
• 15.7. Siemens Healthineers AG
• 15.8. Thermo Fisher Scientific Inc.
• 15.9. Quidel Corporation
• 15.10. Trinity Biotech PLC

16. Strategic Recommendations

17. About Us & Disclaimer